RE:RE:RE:RE:we already have several pieces of news incoming this quarterStill waiting for the FDA link, not the company guesses. In Newcamo's post below they also said H1 2020 which we know LMNL missed; even after your ID's posting it a million times as you once said. LOL
Show us the FDA link. You can't, its obvious.
GunnerG wrote: Can you provide the link where the FDA said that specfically about Ryplazim. Should be a better read than foofs great report with all its missing figures and old company name.
Do your own DD is correct.
Newcamo wrote: The FDA has indicated that the submission of the amended BLA for Ryplazim® will not impact the previously granted designations, including the Priority Review Status, the Orphan Drug Designation and the Rare Pediatric Disease Designation for Ryplazim® for the treatment of PLDG.
The Company expects to be filing an amendment to the BLA in H1 2020 .
--------------------------
read it somewhere as well, dont have time to look it up, but it's somewhere on the site, the distribution partner will be announced next days/weeks to be ready for commercialisation for riplazym obviously.